42 results about "Bronchitides" patented technology

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

The invention provides an infectious bronchitis virus antigen epitope fusion peptide, and the prepared antigen epitope fusion peptide can be used for preparing an antibody and can also be used as a coating antigen for preparing an indirect ELISA detection product. The amino acid sequence of the provided epitope fusion peptide is SEQ ID NO: 4. After antigen epitope analysis is performed on S1 protein of an infectious bronchitis virus strain through bioinformatics software, a plurality of antigen epitopes are fused to obtain the antigen epitope fusion peptide. Specificity tests show that the prepared antigen epitope fusion peptide is a coating antigen, does not have cross reaction with positive serum of other common pathogens, and only has good reaction with positive serum of GI-19 type IBV, that is, the antigen epitope fusion peptide has good serotype specificity as a detection antigen, and has small cross reaction with non-GI-19 type IBV antibody.

The invention belongs to the technical field of biology, and particularly relates to a primer probe composition and a kit for simultaneously detecting IBV (Infectious Bursal Virus) and six genotypes thereof. The primer probe composition is used for detecting the avian infectious bronchitis virus of the GI-1 genotype, the avian infectious bronchitis virus of the GI-13 genotype, the avian infectious bronchitis virus of the GI-19 genotype and the avian infectious bronchitis virus of the GI-22 genotype. The kit is used for detecting the avian infectious bronchitis virus of GVI-1 genotype, detecting the avian infectious bronchitis virus of GI-7 genotype or detecting the avian infectious bronchitis virus of general genotype. The method is high in detection flux, can finish typing and general detection of six genotypes in a single-tube reaction system, and is time-saving and efficient; the channel utilization rate is high, and each fluorescent channel supports typing of two genotypes, so that multiple capabilities are effectively expanded; the typing accuracy is high, typing signals are clear, and the accuracy rate is high.

The invention provides an infectious bronchitis virus subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of genetic engineering vaccines. According to the chicken infectious bronchitis virus mutant protein disclosed by the invention, the amino acid sequence of the mutant protein is shown as SEQ ID NO.5. According to the avian infectious bronchitis virus subunit vaccine containing the recombinant avian infectious bronchitis virus mutant protein Kozak-IgKsp-IBV-M41-S-core-6His as an effective component, the glycosylation level of the vaccine is relatively high, the expression level is relatively stable, the virus return risk of a live vaccine does not exist, the safety is high, large-scale industrial preparation can be achieved, and the vaccine has good application prospects. The cost is low.

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

The present invention belongs to the field of biotechnology, and specifically relates to a primer-probe combination and a kit for simultaneously detecting IBV and its six genotypes. The primer-probe combination is for detecting GI-1 genotype of avian infectious bronchitis virus, for detecting GI-13 genotype of avian infectious bronchitis virus, for detecting GI-19 genotype of avian infectious bronchitis virus, for detecting GI-22 genotype of avian infectious bronchitis virus, for detecting GVI-1 genotype of avian infectious bronchitis virus, for detecting GI-7 genotype of avian infectious bronchitis virus or for detecting universal genotype of avian infectious bronchitis virus. The detection throughput of the present invention is high, and typing and universal detection of six genotypes can be completed in a single-tube reaction system, which is time-saving and efficient; the channel utilization rate is high, and each fluorescent channel supports typing of two genotypes, effectively expanding the multiplexing capability; the typing accuracy is strong, the typing signal is clear, and the accuracy rate is high.

The present application belongs to the field of veterinary drugs, and provides a recombinant protein S-Trimer of an infectious bronchitis virus antigen and a subunit vaccine therefor. Provided in the present application is a recombinant protein S-Trimer of an infectious bronchitis virus antigen, wherein the recombinant protein S-Trimer of the antigen has an amino acid sequence as set forth in SEQ ID No. 4. Also provided in the present application is an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer described above. The present application provides a subunit vaccine for an infectious bronchitis virus, wherein the subunit vaccine comprises a pharmaceutically acceptable carrier and an immunogenic amount of the infectious bronchitis virus antigen.

The invention relates to the technical field of poultry rearing preparations, and discloses a forage natural plant preparation through probiotic fermentation and a preparation method and application thereof, and the preparation method comprises the following steps: preparing a forage natural plant preparation micro powder mixture, preparing a forage natural plant preparation culture substrate, and preparing the forage natural plant preparation through probiotic fermentation. According to the invention, the forage natural plant preparation fermented by probiotics is used as a composite component, so that polysaccharide, starch, cellulose and active pharmaceutical ingredients in forage natural plants are promoted to be further converted and decomposed to form active ingredients which are easier to absorb, the number and activity of the probiotics are improved, the growth and release of the probiotics and metabolites thereof are facilitated, and the forage natural plant preparation can be used as a feed. The chicken bronchitis prevention and treatment effect is obviously higher than that of traditional Chinese veterinary medicine powder.

The invention provides a Chinese herbal medicine preparation for treating avian infectious bronchitis virus variant infection, and relates to the technical field of medicine preparation. The Chinese herbal medicine preparation for treating avian infectious bronchitis virus variant infection is prepared from the following components in parts by weight: 12-20 parts of gynostemma pentaphyllum, 8-12 parts of fructus forsythiae, 4-8 parts of folium isatidis, 4-8 parts of honeysuckle, 12-20 parts of platycodon grandiflorum, 8-12 parts of perillaseed, 4-8 parts of codonopsis pilosula, 4-8 parts of scutellaria baicalensis and 4-8 parts of radix sophorae flavescentis. The Chinese herbal medicines are decocted into liquid medicine to feed poultry, bronchitis and complications caused by virus variant infection can be effectively treated, the physique of the poultry is enhanced, the immunity of the poultry is improved, the death rate of the poultry is reduced, the Chinese herbal medicines are decocted into the liquid medicine, feeding is easy, cost is low, and the Chinese herbal medicines are suitable for large-scale popularization and application. Even if the composition is taken for a long time, drug resistance generated in poultry bodies is low, and drug property residual quantity is small.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

The invention discloses a recombinant serum 4 type fowl adenovirus FAdV4-IBV-QXS1-rf2 carrying an infectious bronchitis S1 gene, wherein a gene locus of the serum 4 type fowl adenovirus Fiber-2 is replaced by an S1 protein gene of an infectious bronchitis virus QX subtype. According to the FAdV4-IBV-QXS1-rf2 recombinant virus, the CRISPR / cas9 technology is used for gene editing of the serum type 4 fowl adenovirus, the pathogenicity of the virus is reduced, meanwhile, high immunogenicity is reserved, and the FAdV4-IBV-QXS1-rf2 recombinant virus which is high in purity and can be inherited stably is obtained. The recombinant virus can activate mucous membrane and humoral immunity of chicken, achieves a dual immune protection effect on FAdV-4 and IBV-QX infection, overcomes the defect of single targeting of traditional vaccines, and provides a general technical path for research and development of multi-combined vaccines of avian influenza, Newcastle disease and other poultry viruses.

The present application provides an antibody targeting chicken egg drop syndrome virus and a kit for detecting chicken egg drop syndrome. The antibody of the present application can recognize different strains of chicken egg drop syndrome virus, and does not cross-react with viruses such as fowl adenovirus I group type 4 (FAdV) and chicken infectious bronchitis virus (IBV). Therefore, it can be used to detect EDSV virus without cross-reacting with other viruses, and has high specificity and sensitivity.

The application provides a general avian infectious bronchitis virus whole genome deep sequencing method and application. The method realizes efficient amplification of long fragments of whole genomes of different genotype IBV epidemic strains by designing and applying a set of combinations containing 24 pairs of specific primers. The specific sequences of the primer combinations are shown in SEQ NO:1 to SEQ NO:48. Compared with a traditional sequencing method, the application significantly reduces the sequencing cost. Only two PCR reactions are needed, and more than 27 kb of IBV full-length genome sequence can be successfully obtained, which provides a more economical and efficient solution for IBV related scientific research and molecular epidemiology monitoring, and helps to promote the development of related field scientific research.

The invention relates to the field of virus detection, in particular to a kit, primer and probe combination for simultaneously detecting avian influenza virus, Newcastle disease virus and infectious bronchitis virus. The kit disclosed by the invention comprises a nucleic acid amplification reagent, wherein the nucleic acid amplification reagent contains primers as shown in SEQ ID NO: 1 to SEQ ID NO: 6 and probes as shown in SEQ ID NO: 7 to SEQ ID NO: 9. The invention designs three pairs of primers and probes aiming at three pathogens of avian influenza virus, Newcastle disease virus and infectious bronchitis virus, and the primers and probes have good sensitivity and specificity and do not have non-specific reaction.

The invention belongs to the technical field of research and development of quintuplet vaccines, and particularly relates to a chicken Newcastle disease virus strain LaSota, a chicken Newcastle disease virus strain H120, a chicken Newcastle disease virus strain N49, a chicken Newcastle disease virus strain FADV-4 and a chicken Newcastle disease virus strain HN01. The chicken Newcastle disease virus strain HN01 and the chicken Newcastle disease virus strain HN01 and the chicken Newcastle disease virus strain HN01 and the chicken Newcastle disease virus strain FADV-4 and the chicken Newcastle disease virus strain HN01 and the chicken Newcastle disease virus strain FADV-4 and the chicken Newcastle disease virus strain HN01 are combined. The chicken Newcastle disease virus LaSota strain is proliferated in chicken embryo fibroblasts or chicken kidney cells, and the chicken Newcastle disease virus LaSota strain and the preparation method thereof have the beneficial effects that the chicken Newcastle disease virus LaSota strain and the preparation method thereof can be used for preparing the chicken Newcastle disease virus LaSota strain. The preparation method comprises the following steps: selecting an inactivated newcastle disease virus LaSota strain, an inactivated bronchitis H120 strain, an inactivated bursal disease N49 strain, an inactivated fowl adenovirus FADV-4 strain and an inactivated mycoplasma synovium HN01 strain; it can be guaranteed that a follow-up vaccine has the advantages of being low in toxicity, high in biological safety, high in cross protection capacity, high in immune response speed, long in antibody protection period, high in cellular immune level and high in virus culture content.

The invention provides a diaminopyrimidine compound with a structure as shown in a formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, and an application of the diaminopyrimidine compound, or the stereoisomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof, or the prodrug molecule thereof, or the deuteride thereof, or the tritium thereof. The diaminopyrimidine compound provided by the invention has obvious inhibitory activity on RSV virus, has a chemical structure type completely different from that of the existing anti-RSV drug ribavirin and the like, is expected to be developed into a novel anti-RSV drug, is used for inhibiting replication or reproduction of the RSV virus, and has broad application prospects. The pharmaceutical composition can be used for preventing, relieving and / or treating respiratory syncytial virus infection and cytopathic effects caused by the respiratory syncytial virus infection, and can be used for treating bronchitis or pneumonia and other diseases caused by the respiratory syncytial virus infection.

The present invention discloses an ELISA antibody detection kit for avian infectious bronchitis virus nsp4 and its application, belonging to the field of immunological detection methods. The kit uses recombinant non-structural protein 4 of avian infectious bronchitis virus as the coating antigen; the nucleotide sequence of the coding gene of the recombinant non-structural protein 4 of avian infectious bronchitis virus is as shown in SEQ ID NO: 3, and its amino acid sequence is as shown in SEQ ID NO: 2. The present invention has successfully established an indirect ELISA detection kit and method for antibodies against non-structural protein 4 of avian infectious bronchitis virus. This method has high specificity, strong sensitivity, and good repeatability. The coefficient of variation of within-batch repeatability is 4.6%, and the coefficient of variation of between-batch repeatability does not exceed 7%. It can be applied to the detection of large-scale serum samples, providing a new selection method for serological diagnosis and immune monitoring of IBV, and having good prospects for popularization and application.

There is provided a method of protecting an offspring of a hen from infectious bronchitis infection, the method comprising administering to the hen a vaccine comprising an inactivated infectious bronchitis virus supplemented with a water-in-oil emulsion and an immunostimulatory oligonucleotide.

The invention relates to the field of preparation of poultry vaccines, in particular to a preparation method of a chicken newcastle disease and avian influenza combined vaccine, which comprises the following steps: respectively inoculating susceptible chick embryos with Newcastle disease virus, infectious bronchitis virus and avian influenza virus, and harvesting infected chick embryo liquid to obtain first virus liquid, second virus liquid and third virus liquid; inoculating the susceptible duck embryo with the egg drop syndrome virus, and harvesting infected duck embryo liquid to obtain a fourth antigen; and concentrating the harvested first virus liquid, second virus liquid, third virus liquid and fourth antigen, inactivating, and mixing and emulsifying with an adjuvant. The vaccine prepared by the invention does not generate any adverse reaction to chickens, is high in experimental safety, can induce high-level neutralizing antibodies in immunized chickens, and can effectively reduce the incidence of Newcastle disease virus, infectious bronchitis virus, egg drop syndrome and avian influenza.

The present invention refers in general to the field of veterinary medicine and especially to the development of vectored vaccines using the Gallid alphaherpesvirus 3 (GaHV-3) or Marek's disease serotype 2 (MDV-2) vector, which contains protective antigens against different avian pathogens such as Newcastle disease virus (NDV), avian infectious laryngotracheitis virus (ILTV), infectious bursal disease virus (IBDV) or Gumboro disease virus, avian influenza virus (AIV), infectious bronchitis virus (IBV).

This invention discloses a chicken infectious bronchitis virus (IBBV) nanoparticle, its preparation method, and its application, belonging to the field of poultry vaccine technology. The nanoparticles are formed by the self-assembly of an SRBD-SpyTag fusion protein and a Ferritin-SpyCatcher fusion protein via a SpyTag / SpyCatcher covalent linkage system. The SRBD-SpyTag fusion protein is formed by fusing a SpyTag sequence to the N-terminus or C-terminus of the S1 protein receptor-binding domain of IBV. The nanovaccine prepared from these nanoparticles exhibits high safety, rapid antigen module replacement, and is suitable for preventing IBV infection. The technical solution of this invention has advantages such as structural stability, strong immunogenicity, and rapid iteration, providing a novel vaccine solution for poultry disease control.

The present disclosure relates to a three-dimensional structure including an inverted co-culture having an interior layer comprising a plurality of cells of a first cell type; an opposing exterior layer comprising a plurality cells of a second cell type; and a basement membrane matrix positioned between the interior layer and the exterior layer, wherein the three-dimensional structure has a diameter, and wherein said diameter is capable of being altered by an alloimmune reaction that disrupts the plurality of cells of the second cell type and leads to contraction of the plurality of cells of the second cell type. Also disclosed is a method of modeling Bronchiolitis Obliterans Syndrome, a method for assessing presence of or risk of developing a physiological condition, a method of identifying one or more biomarkers of a disease, and a method of a method of making a three-dimensional structure.

A bacteria-based compound for the prevention and treatment of a number of strains of avian influenza via oral intake by way of feed or drinking water or both. The agent is an inventive treatment compound comprising a bacterial-based culture which is directed to the prevention and treatment of avian influenza primarily for use in commercial birds such as poultry. The inventive treatment compound disclosed herein is produced from a lipopolysaccharide of a Gram-negative bacterial strain of the Brevundimonas group. The compound may be delivered to poultry by way of liquid or dry feed according to an effective prescribed regimen. A similar treatment approach may be taken as well after the bird is infected. Use of the composition is effective in the prevention and treatment of a variety of avian influenza, including high pathogenicity avian influenza, low pathogenicity avian influenza, Newcastle disease virus, infectious bronchitis disease virus, and infectious laryngotracheitis virus.

This invention relates to the field of biotechnology, specifically disclosing a detection element, kit, and detection method for detecting infectious bronchitis virus (IBV) in chickens. The detection element is a Toehold Switch element, which is an S4-3 element and / or an S3 element; the nucleotide sequence of the S4-3 element is shown in SEQ ID NO: 1; the nucleotide sequence of the S3 element is shown in SEQ ID NO: 2. The detection element of this invention features high sensitivity and strong specificity, enabling the differentiation of three IBV strains—P65, MH20, and H120—at a single-base resolution.

The invention provides a primer and probe composition for typing detection of an infectious bronchitis virus. The composition is used for detecting genotypes of 4 / 91, TC07-2, LDT3, QX, LSC-99I and TW. The invention also provides a detection kit containing the primer and probe composition and a detection method. According to the invention, the detection of six genotypes is integrated into only two reaction tubes, the reaction steps are obviously reduced, the flux is improved, and a great leap is realized in multiple detection capability and detection efficiency, so that the kit is suitable for large-scale clinical screening and epidemiological investigation. The invention provides an unprecedented convenient and accurate tool for the diagnosis of complex clinical mixed infection by effectively identifying and combining the mixed infection of a plurality of genotypes through one-time reaction.

Provided herein are non-naturally occurring, broadly reactive antigens derived from influenza viruses or avian infectious bronchitis virus (IBV) that are immunogenic and capable of eliciting a broadly reactive immune response, e.g., a broadly reactive neutralizing antibody response, directed against influenza virus antigens or IBV antigens following introduction into a subject. Also provided are non-naturally, broadly reactive immunogens, vaccines, virus-like particles (VLPs) and compositions comprising the immunogens and vaccines. Methods of generating an immune response in a human or non-human subject by administering the immunogens, vaccines, VLPs, or compositions thereof are provided. In particular, the immunogens comprise broadly reactive hemagglutinin (HA) protein antigens of influenza virus strains, such as H1, H2, H3, H5, or H7, or of IBV. The immunogens also comprise broadly reactive viral neuraminidase (NA) protein antigens.

The invention discloses a GI-19 pedigree chicken infectious bronchitis virus adapted to replication and proliferation of an African green monkey kidney cell line and application of the GI-19 pedigree chicken infectious bronchitis virus, and belongs to the technical field of attenuated vaccines. The invention aims to provide a GI-19 pedigree IBV attenuated vaccine strain adapted to a Vero in-vitro cell line, which has good safety to both chick embryos and chickens and can stimulate effective immune protection after immunizing the chickens and the immune chick embryos. The invention provides a GI-19 pedigree avian infectious bronchitis virus attenuated strain adapted to replication and proliferation of an African green monkey kidney cell line, which is preserved in China General Microbiological Culture Collection Center on February 13, 2025, and the preservation number is CGMCC NO.46375. The invention further provides a preparation method of the GI-19 pedigree avian infectious bronchitis virus attenuated strain. The method is used for in-vitro proliferation candidate strains of viruses required by avian infectious bronchitis vaccines, diagnostic preparations and the like, and has important practical application value.

The invention discloses a chicken infectious bronchitis prediction method based on an AI chip, and relates to the technical field of animal epidemic disease intelligent monitoring and prediction, and the method comprises the following steps: S001, building a nanosecond-level unified time reference, continuously collecting chicken house environment sound signals through a distributed acoustic collection unit, generating a phase and energy joint spectrum according to the time reference, and carrying out the detection of the phase and energy joint spectrum; and stripping fundamental tone and harmonic components of low-frequency mechanical vibration by using a spectral difference operator to form a dynamic reference signal with separated sound sources. According to the method, the acoustic processing link is driven through the nanosecond time base, dynamic extraction and reconstruction of cough sound are achieved, a false alarm path is recognized in combination with residual density and confidence gating, an interference field is constructed through inverse sound wave injection, the recognition threshold value is dynamically adjusted, and the prediction precision and stability of an AI chip in a high-noise environment are improved.

The invention relates to the field of poultry vaccine preparation, in particular to a new tributary glandular smooth quintuplet inactivated vaccine and a preparation method thereof.The vaccine is prepared from, by mass, 2-3 parts of a water phase and 3-5 parts of an oil phase; wherein the water phase is prepared from the following components in parts by mass: 10 to 25 parts of adjuvant; 10-20 parts of a first antigen containing inactivated avian influenza virus; 10-20 parts of a second antigen containing inactivated infectious bronchitis virus; 10-20 parts of a third antigen comprising an inactivated Newcastle disease virus; 10 to 20 parts of a fourth antigen containing inactivated chicken mycoplasma synoviae; the composition comprises 10-20 parts of a fifth antigen of inactivated fowl adenovirus, and the total parts are 100. The vaccine prepared by the invention does not generate any adverse reaction to chickens, is high in experimental safety, and can induce high-level neutralizing antibodies in immunized chickens, which indicates that the immunized chickens can effectively resist attack of Newcastle disease virus, avian influenza, infectious bronchitis virus, adenovirus and mycoplasma synoviae.

An isolated infectious bronchitis (IB) virus (IBV) QX1285 strain under accession number DPS RE RSCIC 41 in the IZSLER biobank. A vaccine comprising the isolated infectious bronchitis virus and a carrier. The virus may be inactivated. The virus may alternatively be live and attenuated. The vaccine may be formulated for an avian. The avian may be a chicken. The vaccine may be administrated via drinking water. Also claimed is an isolated infectious bronchitis virus having an S1 protein encoded by SEQ ID NO: 1 or a sequence having at least 96% sequence identity thereto, for use as a vaccine against infectious bronchitis. Also claimed is a method of vaccinating an avian against infectious bronchitis, comprising administering the vaccine. Also claimed is a process for preparing a live infectious bronchitis vaccine comprising passaging the virus to reduce pathogenicity, harvesting the attenuated virus, and processing the virus to produce a vaccine. The virus may be passaged at least 50 times. The virus may be passaged by culturing in allantoic fluid of chicken embryos.